Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Blanc-Durand F, Yaniz-Galende E, Llop-Guevara A, Genestie C, Serra V, Herencia-Ropero A, Klein C, Berton D, Lortholary A, Dohollou N, Desauw C, Fabbro M, Malaurie E, Bonichon-Lamaichhane N, Dubot C, Kurtz JE, de Rauglaudre G, Raban N, Chevalier-Place A, Ferron G, Kaminsky MC, Kramer C, Rouleau E, Leary A. Blanc-Durand F, et al. Among authors: ferron g. Gynecol Oncol. 2023 Apr;171:106-113. doi: 10.1016/j.ygyno.2023.01.026. Epub 2023 Mar 1. Gynecol Oncol. 2023. PMID: 36868112
Ovarian and peritoneal psammocarcinoma: Results of a multicenter study on 25 patients.
Delhorme JB, Ohayon J, Gouy S, Averous G, Genestie C, Gaichies L, Glehen O, Guilloit JM, Pezet D, Quenet F, Ferron G, Brigand C, Morice P, Honoré C; French Network for Rare Peritoneal Malignancies (RENAPE). Delhorme JB, et al. Among authors: ferron g. Eur J Surg Oncol. 2020 May;46(5):862-867. doi: 10.1016/j.ejso.2019.12.005. Epub 2019 Dec 9. Eur J Surg Oncol. 2020. PMID: 31902591
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Fabbro M, Desauw C, Bonichon-Lamichhane N, Kurtz JE, Follana P, Leheurteur M, Piano FD, Ferron G, De Rauglaudre G, Ray-Coquard I, Combe P, Chevalier-Place A, Joly F, Leary A, Pujade-Lauraine E, Freyer G, Colomban O. You B, et al. Among authors: ferron g. Clin Cancer Res. 2020 Sep 1;26(17):4625-4632. doi: 10.1158/1078-0432.CCR-20-0054. Epub 2020 Mar 24. Clin Cancer Res. 2020. PMID: 32209570 Clinical Trial.
Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group.
Chevrot A, Pouget N, Bats AS, Huchon C, Guyon F, Chopin N, Rousset-Jablonski C, Beurrier F, Lambaudie E, Provansal M, Sabatier R, Heinemann M, Ngo C, Bonsang-Kitzis H, Lecuru F, Bailly E, Ferron G, Cornou C, Lardin E, Leblanc E, Philip CA, Ray-Coquard I, Hequet D. Chevrot A, et al. Among authors: ferron g. Gynecol Oncol. 2020 Apr;157(1):29-35. doi: 10.1016/j.ygyno.2019.12.046. Gynecol Oncol. 2020. PMID: 32241341
Severe perioperative morbidity after robot-assisted versus conventional laparoscopy in gynecologic oncology: Results of the randomized ROBOGYN-1004 trial.
Narducci F, Bogart E, Hebert T, Gauthier T, Collinet P, Classe JM, Lecuru F, Delest A, Motton S, Conri V, Ferrer C, Marchal F, Ferron G, Probst A, Thery J, Le Deley MC, Lefebvre D, Francon D, Leblanc E, Lambaudie E. Narducci F, et al. Among authors: ferron g. Gynecol Oncol. 2020 Aug;158(2):382-389. doi: 10.1016/j.ygyno.2020.05.010. Epub 2020 May 25. Gynecol Oncol. 2020. PMID: 32467054 Clinical Trial.
A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
Angeles MA, Rychlik A, Cabarrou B, Spagnolo E, Guyon F, Pérez-Benavente A, Gil-Moreno A, Siegrist J, Querleu D, Mery E, Gladieff L, Hernández A, Ferron G, Martinez A. Angeles MA, et al. Among authors: ferron g. Gynecol Oncol. 2020 Sep;158(3):614-621. doi: 10.1016/j.ygyno.2020.06.495. Epub 2020 Jul 22. Gynecol Oncol. 2020. PMID: 32709536
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
Robelin P, Tod M, Colomban O, Lachuer J, Ray-Coquard I, Rauglaudre G, Joly F, Chevalier-Place A, Combe P, Lortholary A, Hamizi S, Raban N, Ferron G, Meunier J, Berton-Rigaud D, Alexandre J, Kaminsky MC, Dubot C, Leary A, Malaurie E, You B. Robelin P, et al. Among authors: ferron g. Gynecol Oncol. 2020 Oct;159(1):256-263. doi: 10.1016/j.ygyno.2020.07.021. Epub 2020 Jul 22. Gynecol Oncol. 2020. PMID: 32712155 Clinical Trial.
Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer.
Aide N, Fauchille P, Coquan E, Ferron G, Combe P, Meunier J, Alexandre J, Berton D, Leary A, De Rauglaudre G, Bonichon N, Pujade Lauraine E, Joly F. Aide N, et al. Among authors: ferron g. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1998-2008. doi: 10.1007/s00259-020-05092-3. Epub 2020 Nov 21. Eur J Nucl Med Mol Imaging. 2021. PMID: 33221969 Free PMC article.
316 results